{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:13:54Z","timestamp":1778912034456,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T00:00:00Z","timestamp":1321401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1245\/s10434-011-2140-2","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T14:15:05Z","timestamp":1321452905000},"page":"646-655","source":"Crossref","is-referenced-by-count":28,"title":["Combined Analysis of Dihydropyrimidine Dehydrogenase and Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Pancreatic Carcinoma Patients Treated with Adjuvant Gemcitabine Plus S-1 Chemotherapy after Surgical Resection"],"prefix":"10.1245","volume":"19","author":[{"given":"Naru","family":"Kondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taijiro","family":"Sueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,16]]},"reference":[{"key":"2140_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225\u201349.","journal-title":"CA Cancer J Clin."},{"key":"2140_CR2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ejca.2003.10.026","volume":"40","author":"KF Kuhlmann","year":"2004","unstructured":"Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40:549\u201358.","journal-title":"Eur J Cancer."},{"key":"2140_CR3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200\u201310.","journal-title":"N Engl J Med."},{"key":"2140_CR4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267\u201377.","journal-title":"JAMA."},{"key":"2140_CR5","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/sj.bjc.6602513","volume":"92","author":"DD Stocken","year":"2005","unstructured":"Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92:1372\u201381.","journal-title":"Br J Cancer."},{"key":"2140_CR6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjsurg.2007.04.018","volume":"195","author":"Y Murakami","year":"2008","unstructured":"Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg. 2008;195:757\u201362.","journal-title":"Am J Surg."},{"key":"2140_CR7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/jso.21955","volume":"104","author":"N Kondo","year":"2011","unstructured":"Kondo N, Murakami Y, Uemura K, et al. Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection. J Surg Oncol. 2011;104:146\u201354.","journal-title":"J Surg Oncol."},{"key":"2140_CR8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548\u201357.","journal-title":"Anticancer Drugs."},{"key":"2140_CR9","first-page":"1322","volume":"6","author":"D Salonga","year":"2000","unstructured":"Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322\u20137.","journal-title":"Clin Cancer Res."},{"key":"2140_CR10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0959-8049(00)00440-8","volume":"37","author":"Y Mizutani","year":"2001","unstructured":"Mizutani Y, Wada H, Fukushima M, et al. The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur J Cancer. 2001;37:569\u201375.","journal-title":"Eur J Cancer."},{"key":"2140_CR11","first-page":"19","volume":"22","author":"P Huang","year":"1995","unstructured":"Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol. 1995;22:19\u201325.","journal-title":"Semin Oncol."},{"key":"2140_CR12","first-page":"4349","volume":"58","author":"JR Mackey","year":"1998","unstructured":"Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998;58:4349\u201357.","journal-title":"Cancer Res."},{"key":"2140_CR13","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-05-4203","volume":"66","author":"E Giovannetti","year":"2006","unstructured":"Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66:3928\u201335.","journal-title":"Cancer Res."},{"key":"2140_CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","volume":"136","author":"JJ Farrell","year":"2009","unstructured":"Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136:187\u201395.","journal-title":"Gastroenterology."},{"key":"2140_CR15","unstructured":"(UICC) IUAC. TMN classification of malignant tumors. 7th ed. New York: Wiley-Liss, 2010."},{"key":"2140_CR16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11605-008-0650-4","volume":"13","author":"Y Murakami","year":"2009","unstructured":"Murakami Y, Uemura K, Sudo T, et al. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Surg. 2009;13:85\u201392.","journal-title":"J Gastrointest Surg."},{"key":"2140_CR17","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/01.sla.0000143300.49878.51","volume":"240","author":"S Nakayama","year":"2004","unstructured":"Nakayama S, Takeda S, Kawase Y, Inoue S, Kaneko T, Nakao A. Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. Ann Surg. 2004;240:840\u20134.","journal-title":"Ann Surg."},{"key":"2140_CR18","first-page":"1223","volume":"14","author":"S Kamoshida","year":"2005","unstructured":"Kamoshida S, Shiogama K, Shimomura R, et al. Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep. 2005;14:1223\u201330.","journal-title":"Oncol Rep."},{"key":"2140_CR19","doi-asserted-by":"crossref","unstructured":"v Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707\u201323.","DOI":"10.1002\/sim.4780141510"},{"key":"2140_CR20","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"304","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073\u201381.","journal-title":"JAMA."},{"key":"2140_CR21","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513\u20138.","journal-title":"J Clin Oncol."},{"key":"2140_CR22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00280-008-0714-x","volume":"63","author":"H Kuramochi","year":"2008","unstructured":"Kuramochi H, Hayashi K, Uchida K, et al. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chemother Pharmacol. 2008;63:85\u20139.","journal-title":"Cancer Chemother Pharmacol."},{"key":"2140_CR23","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.bjc.6602139","volume":"91","author":"W Ichikawa","year":"2004","unstructured":"Ichikawa W, Takahashi T, Suto K, et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer. 2004;91:1245\u201350.","journal-title":"Br J Cancer."},{"key":"2140_CR24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/sj.bjc.6605105","volume":"101","author":"M Kikuchi","year":"2009","unstructured":"Kikuchi M, Mikami T, Sato T, et al. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br J Cancer. 2009;101:116\u201323.","journal-title":"Br J Cancer."},{"key":"2140_CR25","first-page":"709","volume":"22","author":"Y Fukui","year":"2008","unstructured":"Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD, Fukushima M. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med. 2008;22:709\u201316.","journal-title":"Int J Mol Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-011-2140-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-011-2140-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-011-2140-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T16:45:40Z","timestamp":1572972340000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-011-2140-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,16]]},"references-count":25,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["2140"],"URL":"https:\/\/doi.org\/10.1245\/s10434-011-2140-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,16]]}}}